CD274 and classic Hodgkin lymphoma: Simultaneously, a range of malignant tumors has benefited from anti-PD-1/PD-L1 therapy, such as melanoma, non-small-cell lung cancer (NSCLC), small cell lung cancer (SCLC), renal cell carcinoma (RCC), classical Hodgkin lymphoma (cHL), head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), primary mediastinal large B-cell lymphoma (PMLBCL), Merkel cell carcinoma (MCC), etc.